3.1101.30% ( +0.040 )
Trading: Oct 9, 14:14:03 (EDT)Current ValuationThe current P/E ratio is -3.71, within the reasonable range, cheaper than 66.85% of the time in the past 5 years, and the industry ranks 345/602, the industry Median -2.07.
-3.71xP/E
$3.07Stock price
$-0.83Earnings per share
-3.71xP/E
Stock price$3.07Earnings per share$-0.83
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -2.58x
- Typical range
- -6.29x–-1.23x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
020406080
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -56.30x | 148.64% | $182.40B |
MRNAUSModerna | -24.96x | 15.52% | $78.65B |
CSLLYUSCSL Limited | -23.42x | -- | $60.39B |
NTRAUSNatera | -292.86x | 6.99% | $56.33B |
RVMDUSRevolution Medicines | -22.80x | 62.23% | $40.32B |
ROIVUSRoivant Sciences | -92.81x | 146.49% | $24.71B |
BNTXUSBioNTech SE | -11.81x | 19.72% | $23.13B |
INSMUSInsmed | -25.07x | 74.21% | $21.94B |
SMMTUSSummit Therapeutics | -16.00x | 19.55% | $13.70B |
BBIOUSBridgebio Pharma | -18.38x | 28.48% | $12.71B |
MDGLUSMadrigal Pharma | -33.89x | 51.06% | $11.02B |
IBRXUSImmunityBio | -10.58x | 151.32% | $10.50B |
TWSTUSTwist Bioscience | -73.22x | 28.88% | $10.01B |
PCVXUSVaxcyte | -9.09x | 49.36% | $9.67B |
KYMRUSKymera Therapeutics | -30.33x | 4.94% | $9.09B |
CYTKUSCytokinetics | -9.64x | 6.46% | $8.62B |
ARWRUSArrowHead Pharma | -26.82x | 36,308.30% | $8.58B |
ABVXUSAbivax SA | -16.67x | 22.49% | $7.76B |
PRAXUSPraxis Precision Medicines | -21.70x | 3.05% | $7.36B |
IONSUSIonis Pharma | -12.73x | 50.60% | $7.20B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
